{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:47:01Z","timestamp":1784519221942,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.euo.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:54:21Z","timestamp":1718240061000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 P.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicklas","family":"Pfanzelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Dalglish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Shaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.05.009_b0005","unstructured":"AstraZeneca. A randomised, double-blind, placebo-controlled, multicentre phase iii study of olaparib plus abiraterone relative to placebo plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer (PROpel study). clinicaltrials.gov; 2023."},{"key":"10.1016\/j.euo.2024.05.009_b0010","unstructured":"Janssen Research & Development, LLC. A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in subjects with metastatic prostate cancer. clinicaltrials.gov; 2023."},{"key":"10.1016\/j.euo.2024.05.009_b0015","unstructured":"Pfizer. A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer. clinicaltrials.gov; 2023."},{"key":"10.1016\/j.euo.2024.05.009_b0020","unstructured":"ASCO Daily News. Clinical News from the American Society of Clinical Oncology. TALAPRO-2 supports first-line talazoparib\/enzalutamide in all-comers with mCRPC. 2023. https:\/\/dailynews.ascopubs.org\/do\/talapro-2-supports-first-line-talazoparib-enzalutamide-all-comers-mcrpc."},{"key":"10.1016\/j.euo.2024.05.009_b0025","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0030","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2024.05.009_b0035","article-title":"FDA D.I.S.C.O. burst edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer","author":"Food","year":"2023","journal-title":"U.S. Food and Drug Administration (FDA)"},{"key":"10.1016\/j.euo.2024.05.009_b0040","series-title":"FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer","author":"Food","year":"2023"},{"key":"10.1016\/j.euo.2024.05.009_b0045","unstructured":"U.S. Food and Drug Administration. FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer. 2023."},{"key":"10.1016\/j.euo.2024.05.009_b0050","unstructured":"AstraZeneca. Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer. 2022. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/lynparza-approved-in-eu-for-prostate-cancer.html."},{"key":"10.1016\/j.euo.2024.05.009_b0055","unstructured":"AstraZeneca. Lynparza plus abiraterone approved in Japan for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. 2023. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/lynparza-plus-abiraterone-approved-japan-treatment-brca-mutated-metastatic-castration-resistant-prostate-cancer.html."},{"key":"10.1016\/j.euo.2024.05.009_b0060","unstructured":"AstraZeneca. Health Canada approves Lynparza in combination with abiraterone and prednisone or prednisolone for patients with BRCA mutated metastatic castration-resistant prostate cancer. https:\/\/www.newswire.ca\/news-releases\/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer-809616357.html."},{"key":"10.1016\/j.euo.2024.05.009_b0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2020.08.016","article-title":"Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer","volume":"159","author":"Eakin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0070","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0075","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.05.009_b0080","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0085","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.euo.2024.05.009_b0095","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.euo.2024.05.009_b0100","unstructured":"U.S. Food and Drug Administration. FDA approves olaparib, rucaparib to treat prostate cancer\u2014NCI 2020. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-olaparib-rucaparib-prostate-cancer."},{"key":"10.1016\/j.euo.2024.05.009_b0105","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/CMAR.S335962","article-title":"Guidelines for management of treatment-emergent adverse events during rucaparib treatment of patients with metastatic castration-resistant prostate cancer","volume":"14","author":"Labadie","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.euo.2024.05.009_b0110","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0115","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.05.009_b0120","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/cncr.33397","article-title":"Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: preliminary findings","volume":"127","author":"Hoogland","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2024.05.009_b0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1040-8428(01)00143-3","article-title":"Radiotherapy-related fatigue","volume":"41","author":"Jereczek-Fossa","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2024.05.009_b0130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"10.1016\/j.euo.2024.05.009_b0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/qhc.11.4.358","article-title":"Research methods used in developing and applying quality indicators in primary care","volume":"11","author":"Campbell","year":"2002","journal-title":"Qual Saf Health Care"},{"key":"10.1016\/j.euo.2024.05.009_b0140","series-title":"The RAND\/UCLA appropriateness method user\u2019s manual","year":"2001"},{"key":"10.1016\/j.euo.2024.05.009_b0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An adaptation of the RAND\/UCLA modified Delphi Panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"key":"10.1016\/j.euo.2024.05.009_b0150","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1287\/mnsc.9.3.458","article-title":"An experimental application of the Delphi method to the use of experts","volume":"9","author":"Dalkey","year":"1963","journal-title":"Manag Sci"},{"key":"10.1016\/j.euo.2024.05.009_b0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S0266462300002774","article-title":"A method for the detailed assessment of the appropriateness of medical technologies","volume":"2","author":"Brook","year":"1986","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.euo.2024.05.009_b0160","doi-asserted-by":"crossref","first-page":"e828","DOI":"10.1200\/JOP.2016.010686","article-title":"Defining high-quality palliative care in oncology practice: an American Society of Clinical Oncology\/American Academy of Hospice and Palliative Medicine guidance statement","volume":"12","author":"Bickel","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.euo.2024.05.009_b0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MPA.0b013e31826d3a17","article-title":"Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified Delphi process","volume":"42","author":"Strosberg","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.euo.2024.05.009_b0170","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11102-017-0801-2","article-title":"Follow-up intervals in patients with Cushing\u2019s disease: recommendations from a panel of experienced pituitary clinicians","volume":"20","author":"Geer","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.euo.2024.05.009_b0175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MLR.0000000000001108","article-title":"Clinical scenarios for which spinal mobilization and manipulation are considered by an expert panel to be inappropriate (and appropriate) for patients with chronic low back pain","volume":"57","author":"Herman","year":"2019","journal-title":"Med Care"},{"key":"10.1016\/j.euo.2024.05.009_b0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/rth2.12457","article-title":"Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND\/UCLA modified Delphi panel method","volume":"5","author":"Cuker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.euo.2024.05.009_b0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/pubmed\/21.4.421","article-title":"Rating the appropriateness of coronary angiography, coronary angioplasty and coronary artery bypass grafting: the ACRE study. Appropriateness of coronary revascularisation study","volume":"21","author":"Hemingway","year":"1999","journal-title":"J Public Health Med"},{"key":"10.1016\/j.euo.2024.05.009_b0190","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/CEOR.S276121","article-title":"Development of a severity classification system for sickle cell disease","volume":"12","author":"Shah","year":"2020","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.euo.2024.05.009_b0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1051-0443(07)61386-4","article-title":"An agenda for research into uterine artery embolization: results of an expert panel conference","volume":"11","author":"Broder","year":"2000","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.euo.2024.05.009_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289009","article-title":"Disciplinary trends in the use of the Delphi method: A bibliometric analysis","volume":"18","author":"Khodyakov","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2024.05.009_b0205","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejim.2013.03.006","article-title":"Cognitive diagnostic error in internal medicine","volume":"24","author":"van den Berge","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.euo.2024.05.009_b0210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.1995.03530080048040","article-title":"Validity of criteria used for detecting underuse of coronary revascularization","volume":"274","author":"Kravitz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2024.05.009_b0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM200103013440906","article-title":"Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization","volume":"344","author":"Hemingway","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.05.009_b0220","unstructured":"National Comprehensive Cancer Network. NCCN. https:\/\/www.nccn.org."},{"key":"10.1016\/j.euo.2024.05.009_b0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","article-title":"Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment","volume":"31","author":"Fabi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0230","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0235","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1200\/JCO.2013.53.4495","article-title":"Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation","volume":"32","author":"Bower","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.05.009_b0240","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; 2006."},{"key":"10.1016\/j.euo.2024.05.009_b0245","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; 2009."},{"key":"10.1016\/j.euo.2024.05.009_b0250","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; 2021."},{"key":"10.1016\/j.euo.2024.05.009_b0255","unstructured":"Patient-Centered Outcomes Research Institute. The Patient-Centered Outcomes Research Institute strategic plan: generating evidence to achieve more efficient, effective, and equitable health care and improve health for all. 2022."},{"key":"10.1016\/j.euo.2024.05.009_b0260","unstructured":"American Society of Clinical Oncology (ASCO). Antiemetics: ASCO guideline update. Drug, dose, schedule recommendations for antiemetic regimens. 2020."},{"key":"10.1016\/j.euo.2024.05.009_b0265","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2011.12.001","volume":"59","author":"Patel","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.euo.2024.05.009_b0270","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjcard.2015.03.057","article-title":"Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)","volume":"116","author":"Bradley","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.euo.2024.05.009_b0275","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"Moreira","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2024.05.009_b0280","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2024.05.009_b0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2022.04.034","article-title":"Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT)","volume":"171","author":"Ternov","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2024.05.009_bib286","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T21:42:44Z","timestamp":1739223764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2588931124001408"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}